Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy.

Birnbaum AK, Karanam A, Marino SE, Barkley CM, Remmel RP, Roslawski M, Gramling-Aden M, Leppik IE.

Epilepsia. 2019 Jun 27. doi: 10.1111/epi.16093. [Epub ahead of print]

PMID:
31247132
2.

Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups.

Mohamed ME, Schladt DP, Guan W, Wu B, van Setten J, Keating BJ, Iklé D, Remmel RP, Dorr CR, Mannon RB, Matas AJ, Israni AK, Oetting WS, Jacobson PA; DeKAF Genomics and GEN03 Investigators.

Am J Transplant. 2019 Apr 6. doi: 10.1111/ajt.15385. [Epub ahead of print]

PMID:
30953600
3.

Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies.

Oetting WS, Wu B, Schladt DP, Guan W, van Setten J, Keating BJ, Iklé D, Remmel RP, Dorr CR, Mannon RB, Matas AJ, Israni AK, Jacobson PA; DeKAF Genomics and GEN-03 Investigators.

Transplantation. 2019 Jun;103(6):1131-1139. doi: 10.1097/TP.0000000000002625.

PMID:
30801552
4.

Analysis of 75 Candidate SNPs Associated with Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A.

Oetting WS, Schladt DP, Dorr CR, Wu B, Guan W, Remmel RP, Iklé D, Mannon RB, Matas AJ, Israni AK, Jacobson PA; DeKAF Genomics and GEN03 Investigators.

Transplantation. 2019 Feb 11. doi: 10.1097/TP.0000000000002659. [Epub ahead of print]

PMID:
30801535
5.

Simultaneous Quantification of 13 Cannabinoids and Metabolites in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry in Adult Epilepsy Patients.

Roslawski MJ, Remmel RP, Karanam A, Leppik IE, Marino SE, Birnbaum AK.

Ther Drug Monit. 2019 Jun;41(3):357-370. doi: 10.1097/FTD.0000000000000583.

PMID:
30520828
6.

Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing.

Dorr CR, Wu B, Remmel RP, Muthusamy A, Schladt DP, Abrahante JE, Guan W, Mannon RB, Matas AJ, Oetting WS, Jacobson PA, Israni AK; for DeKAF Genomics.

Pharmacogenomics J. 2018 Nov 16. doi: 10.1038/s41397-018-0063-z. [Epub ahead of print]

7.

Urinary microbiome associated with chronic allograft dysfunction in kidney transplant recipients.

Wu JF, Muthusamy A, Al-Ghalith GA, Knights D, Guo B, Wu B, Remmel RP, Schladt DP, Alegre ML, Oetting WS, Jacobson PA, Israni AK.

Clin Transplant. 2018 Dec;32(12):e13436. doi: 10.1111/ctr.13436. Epub 2018 Nov 18.

PMID:
30372560
8.

Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.

Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, Matas AJ, Mannon RB, Israni AK, Oetting WS, Jacobson PA.

Clin Transplant. 2018 Dec;32(12):e13424. doi: 10.1111/ctr.13424. Epub 2018 Oct 31.

PMID:
30318646
9.

Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age.

Polepally AR, Brundage RC, Remmel RP, Leppik IE, Pennell PB, White JR, Ramsay RE, Kistner BM, Birnbaum AK.

Epilepsia. 2018 Sep;59(9):1718-1726. doi: 10.1111/epi.14519. Epub 2018 Aug 12.

PMID:
30101556
10.

Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.

Oetting WS, Wu B, Schladt DP, Guan W, Remmel RP, Dorr C, Mannon RB, Matas AJ, Israni AK, Jacobson PA.

Pharmacogenomics. 2018 Feb;19(3):175-184. doi: 10.2217/pgs-2017-0187. Epub 2018 Jan 10.

11.

Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients.

Oetting WS, Wu B, Schladt DP, Guan W, Remmel RP, Mannon RB, Matas AJ, Israni AK, Jacobson PA.

Pharmacogenomics J. 2018 May 22;18(3):501-505. doi: 10.1038/tpj.2017.49. Epub 2017 Nov 21.

PMID:
29160300
12.

Concepts of Genomics in Kidney Transplantation.

Oetting WS, Dorr C, Remmel RP, Matas AJ, Israni AK, Jacobson PA.

Curr Transplant Rep. 2017 Jun;4(2):116-123. doi: 10.1007/s40472-017-0153-x. Epub 2017 May 24.

13.

CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism.

Dorr CR, Remmel RP, Muthusamy A, Fisher J, Moriarity BS, Yasuda K, Wu B, Guan W, Schuetz EG, Oetting WS, Jacobson PA, Israni AK.

Drug Metab Dispos. 2017 Aug;45(8):957-965. doi: 10.1124/dmd.117.076307. Epub 2017 May 22.

14.

Genotype-guided tacrolimus dosing in African-American kidney transplant recipients.

Sanghavi K, Brundage RC, Miller MB, Schladt DP, Israni AK, Guan W, Oetting WS, Mannon RB, Remmel RP, Matas AJ, Jacobson PA.

Pharmacogenomics J. 2017 Jan;17(1):61-68. doi: 10.1038/tpj.2015.87. Epub 2015 Dec 15.

15.

Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.

Oetting WS, Schladt DP, Guan W, Miller MB, Remmel RP, Dorr C, Sanghavi K, Mannon RB, Herrera B, Matas AJ, Salomon DR, Kwok PY, Keating BJ, Israni AK, Jacobson PA; DeKAF Investigators.

Am J Transplant. 2016 Feb;16(2):574-82. doi: 10.1111/ajt.13495. Epub 2015 Oct 20.

16.

Multigene predictors of tacrolimus exposure in kidney transplant recipients.

Pulk RA, Schladt DS, Oetting WS, Guan W, Israni AK, Matas AJ, Remmel RP, Jacobson PA; DeKAF Investigators.

Pharmacogenomics. 2015 Jul;16(8):841-54. doi: 10.2217/pgs.15.42. Epub 2015 Jun 12.

17.

Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology.

Polepally AR, Remmel RP, Brundage RC, Leppik IE, Rarick JO, Ramsay RE, Birnbaum AK.

J Clin Pharmacol. 2015 Oct;55(10):1101-8. doi: 10.1002/jcph.522. Epub 2015 Aug 18.

18.

Safety of an intravenous formulation of lamotrigine.

Conway JM, Birnbaum AK, Leppik IE, Pennell PB, White JR, Rarick JO, Remmel RP.

Seizure. 2014 May;23(5):390-2. doi: 10.1016/j.seizure.2014.01.019. Epub 2014 Jan 31.

19.

Pharmacokinetic study in pigs and in vitro metabolic characterization in pig- and human-liver microsomes reveal marked differences in disposition and metabolism of tiletamine and zolazepam (Telazol).

Kumar A, Mann HJ, Remmel RP, Beilman GJ, Kaila N.

Xenobiotica. 2014 Apr;44(4):379-90. doi: 10.3109/00498254.2013.833362. Epub 2013 Sep 11.

PMID:
24020890
20.

Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.

Teitelbaum AM, Meissner A, Harding RA, Wong CA, Aldrich CC, Remmel RP.

Bioorg Med Chem. 2013 Sep 1;21(17):5605-17. doi: 10.1016/j.bmc.2013.05.024. Epub 2013 May 24.

21.

Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, Leppik IE, Lamba JK.

Pharmacogenomics. 2013 Jan;14(1):35-45. doi: 10.2217/pgs.12.180.

22.

Stability of heroin, 6-monoacetylmorphine, and morphine in biological samples and validation of an LC-MS assay for delayed analyses of pharmacokinetic samples in rats.

Jones JM, Raleigh MD, Pentel PR, Harmon TM, Keyler DE, Remmel RP, Birnbaum AK.

J Pharm Biomed Anal. 2013 Feb 23;74:291-7. doi: 10.1016/j.jpba.2012.10.033. Epub 2012 Nov 15.

23.

9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma.

Teitelbaum AM, Gallardo JL, Bedi J, Giri R, Benoit AR, Olin MR, Morizio KM, Ohlfest JR, Remmel RP, Ferguson DM.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1519-27. doi: 10.1007/s00280-012-1855-5. Epub 2012 Mar 9.

PMID:
22402637
24.

A sensitive capillary GC-MS method for analysis of topiramate from plasma obtained from single-dose studies.

Conway JM, Birnbaum AK, Marino SE, Cloyd JC, Remmel RP.

Biomed Chromatogr. 2012 Sep;26(9):1071-6. doi: 10.1002/bmc.1749. Epub 2012 Jan 4.

25.

Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes.

Zhou J, Argikar UA, Remmel RP.

Pharmacogenomics. 2011 Dec;12(12):1671-9. doi: 10.2217/pgs.11.105. Epub 2011 Nov 2.

PMID:
22047493
26.

Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy.

Aliwarga T, Cloyd JC, Goel V, Brundage RC, Marino SE, Leppik IE, Remmel RP.

Ther Drug Monit. 2011 Feb;33(1):56-63. doi: 10.1097/FTD.0b013e3182081089.

PMID:
21233690
27.

Inhibitors of the salicylate synthase (MbtI) from Mycobacterium tuberculosis discovered by high-throughput screening.

Vasan M, Neres J, Williams J, Wilson DJ, Teitelbaum AM, Remmel RP, Aldrich CC.

ChemMedChem. 2010 Dec 3;5(12):2079-87. doi: 10.1002/cmdc.201000275.

28.

Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.

Zhou J, Tracy TS, Remmel RP.

Drug Metab Dispos. 2011 Feb;39(2):322-9. doi: 10.1124/dmd.110.035030. Epub 2010 Oct 28.

29.

Drug metabolism in hemorrhagic shock: pharmacokinetics of selective markers of cytochrome-P450 2C9, 2D6, and 3A4 enzyme activities in a porcine model.

Kumar A, Remmel RP, Mann HJ, Beilman GJ.

J Surg Res. 2011 May 15;167(2):e231-43. doi: 10.1016/j.jss.2010.06.040. Epub 2010 Sep 8.

PMID:
20850770
30.

Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1.

Zhou J, Tracy TS, Remmel RP.

Drug Metab Dispos. 2010 Nov;38(11):1907-11. doi: 10.1124/dmd.110.033829. Epub 2010 Jul 28.

31.
32.

CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.

Chaudhry AS, Urban TJ, Lamba JK, Birnbaum AK, Remmel RP, Subramanian M, Strom S, You JH, Kasperaviciute D, Catarino CB, Radtke RA, Sisodiya SM, Goldstein DB, Schuetz EG.

J Pharmacol Exp Ther. 2010 Feb;332(2):599-611. doi: 10.1124/jpet.109.161026. Epub 2009 Oct 23.

33.

Studies on induction of lamotrigine metabolism in transgenic UGT1 mice.

Argikar UA, Senekeo-Effenberger K, Larson EE, Tukey RH, Remmel RP.

Xenobiotica. 2009 Nov;39(11):826-35. doi: 10.3109/00498250903188985.

34.

Gene expression and functional analyses of primary rat hepatocytes on nanofiber matrices.

Brophy CM, Luebke-Wheeler JL, Amiot BP, Remmel RP, Rinaldo P, Nyberg SL.

Cells Tissues Organs. 2010;191(2):129-40. doi: 10.1159/000223235. Epub 2009 Jun 1.

PMID:
19494481
35.

Variation in glucuronidation of lamotrigine in human liver microsomes.

Argikar UA, Remmel RP.

Xenobiotica. 2009 May;39(5):355-63. doi: 10.1080/00498250902745082.

PMID:
19387891
36.

Rat hepatocyte spheroids formed by rocked technique maintain differentiated hepatocyte gene expression and function.

Brophy CM, Luebke-Wheeler JL, Amiot BP, Khan H, Remmel RP, Rinaldo P, Nyberg SL.

Hepatology. 2009 Feb;49(2):578-86. doi: 10.1002/hep.22674.

37.

Synthesis of deuterium-labelled 5'-O-[N-(Salicyl)sulfamoyl]adenosine (Sal-AMS-d(4)) as an internal standard for quantitation of Sal-AMS.

Gupte A, Subramanian M, Remmel RP, Aldrich CC.

J Labelled Comp Radiopharm. 2008 Feb;51(2):118-122.

38.

Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10.

Argikar UA, Remmel RP.

Drug Metab Dispos. 2009 Jan;37(1):229-36. doi: 10.1124/dmd.108.022426. Epub 2008 Oct 6.

39.

High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry.

Subramanian M, Birnbaum AK, Remmel RP.

Ther Drug Monit. 2008 Jun;30(3):347-56. doi: 10.1097/FTD.0b013e3181678ecb.

PMID:
18520607
40.
41.

Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension.

Clemens PL, Cloyd JC, Kriel RL, Remmel RP.

Clin Drug Investig. 2007;27(4):243-50.

PMID:
17358096
42.

Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation.

Senekeo-Effenberger K, Chen S, Brace-Sinnokrak E, Bonzo JA, Yueh MF, Argikar U, Kaeding J, Trottier J, Remmel RP, Ritter JK, Barbier O, Tukey RH.

Drug Metab Dispos. 2007 Mar;35(3):419-27. Epub 2006 Dec 6.

PMID:
17151188
43.

Pharmacokinetics of tiletamine and zolazepam (Telazol) in anesthetized pigs.

Kumar A, Mann HJ, Remmel RP.

J Vet Pharmacol Ther. 2006 Dec;29(6):587-9. No abstract available.

PMID:
17083465
44.

Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients.

Argikar UA, Cloyd JC, Birnbaum AK, Leppik IE, Conway J, Kshirsagar S, Oetting WS, Klein EC, Remmel RP.

Epilepsy Res. 2006 Sep;71(1):54-63. Epub 2006 Jul 3.

PMID:
16815679
45.

Determination of constituents of Telazol--tiletamine and zolazepam by a gas chromatography/mass spectrometry-based method.

Kumar A, Mann HJ, Remmel RP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Oct 2;842(2):131-5.

PMID:
16769259
46.

Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients.

Kim SW, Grant JE, Yoon G, Williams KA, Remmel RP.

Clin Neuropharmacol. 2006 Mar-Apr;29(2):77-9.

PMID:
16614539
47.

In vivo oxidative metabolism of a major peroxidation-derived DNA adduct, M1dG.

Otteneder MB, Knutson CG, Daniels JS, Hashim M, Crews BC, Remmel RP, Wang H, Rizzo C, Marnett LJ.

Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6665-9. Epub 2006 Apr 13.

48.

High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media.

Kirstein MN, Hassan I, Guire DE, Weller DR, Dagit JW, Fisher JE, Remmel RP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 1;835(1-2):136-42. Epub 2006 Apr 11.

PMID:
16584929
49.

Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.

Nagar S, Remmel RP.

Oncogene. 2006 Mar 13;25(11):1659-72. Review.

PMID:
16550166
50.

Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens.

Kirstein MN, Brundage RC, Elmquist WF, Remmel RP, Marker PH, Guire DE, Yee D.

Breast Cancer Res Treat. 2006 Apr;96(3):217-25.

PMID:
16502018

Supplemental Content

Loading ...
Support Center